News

AI-based tool to assess muscles, nerves shows promise as biomarker

A newer assessment method known as dEMB, for decomposition electromyography — which uses artificial intelligence (AI) tools to measure nerve and muscle function — strongly correlated with measures of physical function and was able to distinguish people with spinal muscular atrophy (SMA) who were able to walk from those…

Bone health is impaired in SMA children, but treatment may help

Children with spinal muscular atrophy (SMA) generally have poor bone health, including low bone mineral density and reduced bone formation and remodeling, a study indicates. The effect on bone health is more pronounced in children with worse motor function, but as treatment with Spinraza (nusinersen) improved motor function…

Spinraza treatment responses may be predicted by certain RNAs: Study

Certain RNA molecules may be used as biomarkers to assess response to treatment with Spinraza (nusinersen) in people with spinal muscular atrophy (SMA), according to a recent study. These RNA (which stands for ribonucleic acid) molecules are found in the cerebrospinal fluid (CSF), the liquid surrounding the brain…

SMA varies with 4 SMN2 gene copies, gets worse with age

How spinal muscular atrophy (SMA) manifests among people who carry four copies of the SMN2 gene varies, ranging from type 2 to type 4, with functional abilities showing a tendency to decline with age, a study in Italy finds. Understanding how the disease progresses over time and what influences…

Early DMTs may slow scoliosis progression in SMA type 2

Disease-modifying therapies (DMTs) may slow the progression of an abnormal curvature of the spine in people with spinal muscular atrophy (SMA) type 2, a study reported. For those patients treated early, especially ones with no or minimal scoliosis, these findings were particularly significant, according to “Early treatment of…